Literature DB >> 14714906

Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus.

S D Denburg1, J A Denburg.   

Abstract

Nervous system involvement in systemic lupus erythematosus (SLE) is typically diagnosed on the basis of clinical psychiatric and/or neurologic syndromes (NPSLE). Neuropsychological tests can be used to assess nervous system integrity even in the absence of major NP syndromes. Their application has uncovered significant cognitive dysfunction, ranging from mild to severe, in a sizeable proportion of SLE patients irrespective of clinical NP status. Cognitive dysfunction has now been accepted as a bona fide manifestation of NPSLE. The heterogeneity of clinical NPSLE manifestations is paralleled by the diversity of cognitive deficits reported in different studies and within different patients. The success of attempts to explain these deficits on the basis of potential pathogenetic mechanisms, such as antibrain antibodies and proinflammatory cytokines, has been uneven. To date, the most robust findings have emerged in relation to antiphospholipid antibodies, which carry with them important therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714906     DOI: 10.1191/0961203303lu497oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

Review 1.  [Glucocorticoid therapy in collagen diseases diseases].

Authors:  L Unger; M Kayser; M Enderlein; K Manger; H Nüsslein
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

2.  Neurocognitive impairment in childhood-onset systemic lupus erythematosus: measurement issues in diagnosis.

Authors:  Tricia S Williams; Cynthia Aranow; Gail S Ross; Alexandra Barsdorf; Lisa F Imundo; Andrew H Eichenfield; Philip J Kahn; Betty Diamond; Deborah M Levy
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-08       Impact factor: 4.794

3.  Impaired response to amphetamine and neuronal degeneration in the nucleus accumbens of autoimmune MRL-lpr mice.

Authors:  Kelly K Anderson; David A Ballok; Neena Prasad; Henry Szechtman; Boris Sakic
Journal:  Behav Brain Res       Date:  2005-09-23       Impact factor: 3.332

4.  Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution.

Authors:  E Muscal; D R Bloom; J V Hunter; B L Myones
Journal:  Lupus       Date:  2009-12-21       Impact factor: 2.911

Review 5.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 6.  Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood.

Authors:  Ashwaq AlE'ed; Patricia Vega-Fernandez; Eyal Muscal; Claas H Hinze; Lori B Tucker; Simone Appenzeller; Brigitte Bader-Meunier; Johannes Roth; Vicenç Torrente-Segarra; Marisa S Klein-Gitelman; Deborah M Levy; Tresa Roebuck-Spencer; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08-29       Impact factor: 4.794

7.  Markers of acute neuropsychiatric systemic lupus erythematosus: a multidisciplinary evaluation.

Authors:  Essam A Abda; Zahraa I Selim; Moustafa E M Radwan; Nagham M Mahmoud; Omar M Herdan; Khalid A Mohamad; Sherifa A Hamed
Journal:  Rheumatol Int       Date:  2012-10-12       Impact factor: 2.631

8.  Mania: psychiatric manifestations of the antiphospholipid syndrome.

Authors:  Haniya Raza; Steven A Epstein; Maryland Pao; Donald L Rosenstein
Journal:  Psychosomatics       Date:  2008 Sep-Oct       Impact factor: 2.386

Review 9.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

10.  Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?

Authors:  David A Ballok; Boris Sakic
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.